Member Info for E_AL

So £67K worth of sells resulted in around 10% drop?

# Trades 34
Vol. Sold 126,693
Sold Value £67.15k

Make whatever you want out of it ;)

"PRD is way too small (currently) and way too illiquid for this concerted effort to be part of a shorting strategy (it is too difficult and expensive to short this stock to make it worthwhile)."

Sefton, I think its a bit difficult to short "Unborrowable" stock ;)

"Predator Oil & Gas Holdings PLC
Special info:
Unborrowable

https://www.ig.com/uk/shares/markets-shares/predator-oil--gas-holdings-plc "

Thanks Sefton, I know but I wanted to know what his half glass full approach to the sp would be ;)

Unlike many other BB, this board has top quality contributors and I fully admire the amount of time and effort they've put here.

The Company's mcap is tiny compare to its potential and diverse assets it has in the portfolio. I STRONGLY believe that the sp will rerate soon and the recent drop (16p to 5p) followed up by ridiculously low price placing (5p) was for The City mates to get in before rerating again.

Can't wait to hear what Paul has to say next week & I am expecting RNS before the presentation.

" If MOU-4 fails then it's 2-3p for the placing then...."

And if MOU-4 succeeds, where will the sp be in your opinion? :)

# Trades 98

Vol. Sold 288,630
Sold Value £164.52k

Vol. Bought 321,500
Bought Value £183.26k

The stop losses of the 10% profit-making-traders got triggered earlier and sold but the smart money still around hoovering anything below 57p

SP has dropped on small volumes and it will move back up very soon.

An interesting question from the interview:

Q\ Imagine you find yourself in a lift with Warren Buffett. What would be your ‘elevator pitch’ to summarize why he should invest?

A\Abingdon Health is a development and manufacturing engine in a lateral flow testing market that is undergoing a paradigm shift driven in part by the widespread adoption of testing during the COVID-19. Abingdon’s vast experience in lateral flow testing and its investment in the latest automated manufacturing means it is best placed to significantly grow its contract service customer base and own products revenues.

We have made good progress in building a broader contract development and manufacturing organisation, with a number of new contract wins for both COVID and non-COVID products.

We have now completed the latest phase of our capacity expansion plans and have in place state-of-the-art automated manufacturing capacities that will be used to drive value with a number of programmes expected to complete tech transfer and move to volume manufacturing in the next few months.

In 2021 we delivered 123% growth in sales, generating revenues of circa £11.6m for the year ended 30 June 2021 (FY 2020: £5.2m). We are now focussed on the next phase of the Company’s growth as we continue to manufacture an increasing portfolio of products.

Abingdon Health just tweeted:

"@Abingdon_Health : Abingdon Health's CEO, Chris Yates spoke with @sharebuyers where he discussed why he feels the business is one of the best players in the industry to satisfy ongoing #lateralflow test demand.

#ABDX
Learn more: https://www.sharebuyers.co.uk/shares/abingdon-health-on-becoming-engine-lateral-flow-tests/"

https://twitter.com/Abingdon_Health/status/1431263247978598400

"“Abingdon Health is a development and manufacturing engine in a lateral flow testing market that is undergoing a paradigm shift driven in part by the widespread adoption of testing during the COVID-19. Abingdon’s vast experience in lateral flow testing and its investment in the latest automated manufacturing means it is best placed to significantly grow its contract service customer base and own products revenues.”

Chris Yates, Abingdon Health CEO"

Full interview:

https://www.sharebuyers.co.uk/shares/abingdon-health-on-becoming-engine-lateral-flow-tests/

You do realise that Abingdon has a very small ‘free float’. Just 25% of its stock is traded on the market.

Add to that, the company’s shares are unborrowable & only available non-leverage treading.

Over the past couple of days the sp moved up around 9-11am so fingers crossed it will bounce back to 70s shortly

Add to it & according to Omega's tweet:

"Omega Diagnostics @OmegaDiagnostic
·
44m
AbC-19Trade mark sign

Rightwards arrow UK-RTC antibody test opportunities

• Evidence is building around the importance of antibody testing – the media buzz is unmissable at the moment

• We align with Abingdon Health’s view that there will be a *significant* opportunity for this test "

Avacta entered into an agreement with Abingdon Health to ramp up manufacturing capacity of its rapid saliva-based SARS-CoV-2 antigen test. The agreement with Abingdon Health will provide Avacta with additional manufacturing capacity that could increase to several millions of tests per month.

The day traders already sold in 70s, hence we are back to where we started the day ;)

It looks the seller is done

Where did you get your crystal ball from? ha

Yesterdays the sp was hovering around mid 60s then suddenly it ran to high 70s, I am expecting the same today.

I very much agree with you Rick and the market knows it which is why I think someone is manipulating the share price to load up on the cheap. Currently, only 33% of the company's share are in free float, the rest are locked in until December 2021.

IMHO Abingdon's current Mcap cap is undervalued.

GLA

Monday-23rd of Aug. 2021:

# Trades 72

Vol. Sold 113,158
Sold Value £58.84k

Vol. Bought 371,092
Bought Value £192.97k

nothing new in what you just said, why predicting a sudden drop tomorrow?

Gary, any reason why you think The share price will test 30s tomorrow?I’d expect a bounce in Omega & ABDX sp after today’s BBC article not a drop .. Thanks

Why?